MedPath

Effectiveness of Oral Rehydration Therapy Supplemented With Zinc in the Management of Diarrhea Acute

Phase 3
Conditions
Diarrhea
Children
Interventions
Other: Zinc group
Other: Placebo group
Registration Number
NCT02601742
Lead Sponsor
Hospital General Naval de Alta Especialidad - Escuela Medico Naval
Brief Summary

Acute diarrhea is the third cause of infant mortality in the world causing 15% of all deaths in children under 5 years and is responsible for nearly 1.4 million deaths in developing countries. It is considered a self-limiting disease and to this problem the recommendation of the World Health Organization (WHO) is the administration of zinc with low osmolarity oral dehydration salts for a period of 10-14 days which reduces the severity of the episode.

In Mexico COFEPRIS believes the zinc salt as a food supplement and not a drug and the above problem is presented in terms of prescribing and access of this salt to the general population. In Mexico the investigators have the provision and accessibility of low osmolarity oral dehydration salts supplemented with adequate doses of zinc, which is inexpensive for the general population and offering a solution in terms of supply and management.

The purpose of the study involves the evaluation Pedialyte diarrhea in the treatment of acute diarrhea in children under 5 years. The investigator sconsider the use of Pedialyte diarrhea eases their access to the population in general and it is low cost compared with the zinc salt that is sold only in specialized pharmacies under strict medical prescription Objective: Compare the duration of symptoms of acute diarrhea in the treatment with low osmolarity oral rehydration salts (Pedialyte) vs treatment of low osmolarity oral rehydration supplemented with zinc (Pedialyte diarrhea) Study Desing: Double blind, randomized, controlled.

Detailed Description

It will be conducted a randomized controlled double-blind in the Emergency service of the Naval General Hospital of High Specialty in the Mexico City. The period of patient inclusion in the study is October 2015 to November 2016.

The patients selections is the children between 6 months and 5 years who come to the emergency room with symptoms of acute diarrhea with up to 48 hours of starting the disease, it will proceed to questioning and to assess vital signs and thorough physical examination for determine the degree of dehydration, nutritional status and rule out diagnosis of abdominal pathology emergency.

Selection criteria Inclusion

* Patients 6 months to 5 years old with acute diarrhea

* Patients in their first 48 hours of onset diarrhea

* Dehydration mild to moderate according to WHO clinical scale

* Both sexes

* Outpatients

Exclusion

* Patients with vomit (10 or more)

* Hemodynamic Instability

* Dehydration severe

* Patients with heart disease

* Patients with a history of prematurity.

* Patients with chronic diarrhea

* Patients whose parents refuse to provide written informed consent

* Patients who do not comply with treatment correctly

* Patients with suspected surgical pathology

Elimination

* Patients with severe dehydration

* Patients in whom the parents decline for informed consent

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
350
Inclusion Criteria
  • Patients 6 months to 5 years old with acute diarrhea
  • Patients in their first 48 hours of onset diarrhea
  • Dehydration mild to moderate according to WHO clinical scale
  • Both sexes
  • Outpatients
Exclusion Criteria
  • Patients with vomit (10 or more)
  • Hemodynamic Instability
  • Severe dehydration
  • Patients with heart disease
  • Patients with a history of prematurity.
  • Patients with chronic diarrhea
  • Patients whose parents refuse to provide written informed consent
  • Patients who do not comply with treatment correctly
  • Patients with suspected surgical pathology

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Zinc groupZinc groupPedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
Placebo groupPlacebo groupPedialyte oral electrolyte solution, 330 ml per day for 7 days
Primary Outcome Measures
NameTimeMethod
Number of bowel movements per day4 months
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath